knowledge -WSS

knowledge

author：explore 2025-09-29 13:30:43 - browse：6

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： How to bring more disabled researchers into academia

focus

WSS

Humans aren't the only ones with an imagination. Rats have it too

IVF, abortion rights issues kick off Biden’s State of the Union

The drug industry has found itself all alone in Washington

Kidney transplant patients stopped immunosuppressants in trial

Key Senate panel to consider PBM, drug pricing reform package

Prime Medicine says its gene editing passes test in monkeys

hotspot

knowledge

focus

Virginia high school admissions case could be legal follow

Sen. Paul opposes bill to ban Chinese biotechs

Virginia high school admissions case could be legal follow

Humans aren't the only ones with an imagination. Rats have it too

23andMe had bad news about my health. I wish a person had delivered it

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Cancer drug shortages should be causing more outrage

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Trump demands the U.S. pay no more for drugs than other countries … again

Bill would allow buprenorphine prescription for addiction via telehealth

hotspot

CDC marks new Covid

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Air quality improving but still lags in Black, Hispanic communities

Life sciences investors close nearly $6 billion in new funds

The problem with charging patients to message their doctors

Former medical device CEO who sold dummy, plastic parts convicted of fraud

focus

hotspot

focus

leisure time